1
|
Niu ZX, Wang YT, Sun JF, Nie P, Herdewijn P. Recent advance of clinically approved small-molecule drugs for the treatment of myeloid leukemia. Eur J Med Chem 2023; 261:115827. [PMID: 37757658 DOI: 10.1016/j.ejmech.2023.115827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 09/14/2023] [Accepted: 09/20/2023] [Indexed: 09/29/2023]
Abstract
Myeloid leukemia denotes a hematologic malignancy characterized by aberrant proliferation and impaired differentiation of blood progenitor cells within the bone marrow. Despite the availability of several treatment options, the clinical outlook for individuals afflicted with myeloid leukemia continues to be unfavorable, making it a challenging disease to manage. Over the past, substantial endeavors have been dedicated to the identification of novel targets and the advancement of enhanced therapeutic modalities to ameliorate the management of this disease, resulting in the discovery of many clinically approved small-molecule drugs for myeloid leukemia, including histone deacetylase inhibitors, hypomethylating agents, and tyrosine kinase inhibitors. This comprehensive review succinctly presents an up-to-date assessment of the application and synthetic routes of clinically sanctioned small-molecule drugs employed in the treatment of myeloid leukemia. Additionally, it provides a concise exploration of the pertinent challenges and prospects encompassing drug resistance and toxicity. Overall, this review effectively underscores the considerable promise exhibited by clinically endorsed small-molecule drugs in the therapeutic realm of myeloid leukemia, while concurrently shedding light on the prospective avenues that may shape the future landscape of drug development within this domain.
Collapse
Affiliation(s)
- Zhen-Xi Niu
- Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, 450018, China
| | - Ya-Tao Wang
- First People's Hospital of Shangqiu, Henan Province, Shangqiu, 476100, China; Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, 130033, China.
| | - Jin-Feng Sun
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, College of Pharmacy, Yanji, Jilin, 133002, China.
| | - Peng Nie
- Rega Institute for Medical Research, Medicinal Chemistry, KU Leuven, Herestraat 49-Box 1041, 3000, Leuven, Belgium.
| | - Piet Herdewijn
- Rega Institute for Medical Research, Medicinal Chemistry, KU Leuven, Herestraat 49-Box 1041, 3000, Leuven, Belgium.
| |
Collapse
|
2
|
Zhang L, Yuan Y, Yu J, Liu H. SEMCM: A Self-Expressive Matrix Completion Model for Anti-cancer Drug Sensitivity Prediction. Curr Bioinform 2022. [DOI: 10.2174/1574893617666220302123118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Genomic data sets generated by several recent large scale high-throughput screening efforts pose a thorny computational challenge for anticancer drug sensitivity prediction.
Objective:
We aimed to design an algorithm model that would predict missing elements in incomplete matrices and could be applicable to drug response prediction programs.
Method:
We developed a novel self-expressive matrix completion model to improve the predictive performance of drug response prediction problems. The model is based on the idea of subspace clustering and as a convex problem, it can be solved by alternating direction method of
multipliers. The original incomplete matrix can be filled through model training and parameters updated iteratively.
Results:
We applied SEMCM to Genomics of Drug Sensitivity in Cancer
(GDSC) and Cancer Cell Line Encyclopedia (CCLE) datasets to predict
unknown response values. A large number of experiments have proved that the algorithm has good prediction results and stability, which are better than several existing advanced drug sensitivity prediction and matrix
completion algorithms. Without modeling mutation information, SEMCM
could correctly predict cell line-drug associations for mutated cell lines and
wild cell lines. SEMCM can also be used for drug repositioning. The newly
predicted drug responses of GDSC dataset suggest that BL-41 was highly
sensitive to Bortezomib. Moreover, the sensitivity of A172 and NCI-H1437
to Paclitaxel was roughly the same.
Conclusion:
We report an efficient anticancer drug sensitivity prediction algorithm which is open-source and can predict the unknown responses of
cancer cell lines to drugs. Experimental results prove that our method can
not only improve the prediction accuracy but also can be applied to drug
repositioning.
Collapse
Affiliation(s)
- Lin Zhang
- Engineering Research Center of Intelligent Control for Underground
Space, Ministry of Education,
- China University of Mining and Technology, Xuzhou 221116, China
| | - Yuwei Yuan
- Engineering Research Center of Intelligent Control for Underground
Space, Ministry of Education,
- China University of Mining and Technology, Xuzhou 221116, China
| | - Jian Yu
- Engineering Research Center of Intelligent Control for Underground
Space, Ministry of Education,
- China University of Mining and Technology, Xuzhou 221116, China
| | - Hui Liu
- Engineering Research Center of Intelligent Control for Underground
Space, Ministry of Education,
- China University of Mining and Technology, Xuzhou 221116, China
| |
Collapse
|